Angiotensin-Converting Enzyme - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Angiotensin-Converting Enzyme

The Experts below are selected from a list of 151350 Experts worldwide ranked by ideXlab platform

Nancy J Brown – One of the best experts on this subject based on the ideXlab platform.

  • dipeptidyl peptidase iv in angiotensin converting Enzyme inhibitor associated angioedema
    Hypertension, 2008
    Co-Authors: James Brian Byrd, Karine Touzin, Saba Sile, James V Gainer, Chang Yu, John H Nadeau, Albert Adam, Nancy J Brown

    Abstract:

    Angioedema is a potentially life-threatening adverse effect of Angiotensin-Converting Enzyme inhibitors. Bradykinin and substance P, substrates of Angiotensin-Converting Enzyme, increase vascular permeability and cause tissue edema in animals. Studies indicate that amino-terminal degradation of these peptides, by aminopeptidase P and dipeptidyl peptidase IV, may be impaired in individuals with Angiotensin-Converting Enzyme inhibitor–associated angioedema. This case-control study tested the hypothesis that dipeptidyl peptidase IV activity and antigen are decreased in sera of patients with a history of Angiotensin-Converting Enzyme inhibitor–associated angioedema. Fifty subjects with a history of Angiotensin-Converting Enzyme inhibitor–associated angioedema and 176 Angiotensin-Converting Enzyme inhibitor–exposed control subjects were ascertained. Sera were assayed for Angiotensin-Converting Enzyme activity, aminopeptidase P activity, aminopeptidase N activity, dipeptidyl peptidase IV activity, and antigen and the ex vivo degradation half-lives of bradykinin, des-Arg 9 -bradykinin, and substance P in a subset. The prevalence of smoking was increased and of diabetes decreased in case versus control subjects. Overall, dipeptidyl peptidase IV activity (26.6±7.8 versus 29.6±7.3 nmol/mL per minute; P =0.026) and antigen (465.8±260.8 versus 563.1±208.6 ng/mL; P =0.017) were decreased in sera from individuals with Angiotensin-Converting Enzyme inhibitor–associated angioedema compared with Angiotensin-Converting Enzyme inhibitor–exposed control subjects without angioedema. Dipeptidyl peptidase IV activity (21.5±4.9 versus 29.8±6.7 nmol/mL per minute; P =0.001) and antigen (354.4±124.7 versus 559.8±163.2 ng/mL; P =0.003) were decreased in sera from cases collected during Angiotensin-Converting Enzyme inhibition but not in the absence of Angiotensin-Converting Enzyme inhibition. The degradation half-life of substance P correlated inversely with dipeptidyl peptidase IV antigen during Angiotensin-Converting Enzyme inhibition. Environmental or genetic factors that reduce dipeptidyl peptidase IV activity may predispose individuals to angioedema.

  • Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema. Commentary
    Hypertension, 2008
    Co-Authors: Eric Grouzmann, James Brian Byrd, Karine Touzin, Saba Sile, James V Gainer, John H Nadeau, Albert Adam, Thierry Buclin, Nancy J Brown

    Abstract:

    Angioedema is a potentially life-threatening adverse effect of Angiotensin-Converting Enzyme inhibitors. Bradykinin and substance P, substrates of Angiotensin-Converting Enzyme, increase vascular permeability and cause tissue edema in animals. Studies indicate that amino-terminal degradation of these peptides, by aminopeptidase P and dipeptidyl peptidase IV, may be impaired in individuals with Angiotensin-Converting Enzyme inhibitor-associated angioedema. This case-control study tested the hypothesis that dipeptidyl peptidase IV activity and antigen are decreased in sera of patients with a history of Angiotensin-Converting Enzyme inhibitor-associated angioedema. Fifty subjects with a history of Angiotensin-Converting Enzyme inhibitor-associated angioedema and 176 Angiotensin-Converting Enzyme inhibitor-exposed control subjects were ascertained. Sera were assayed for Angiotensin-Converting Enzyme activity, aminopeptidase P activity, aminopeptidase N activity, dipeptidyl peptidase IV activity, and antigen and the ex vivo degradation half-lives of bradykinin, des-Arg 9 -bradykinin, and substance P in a subset. The prevalence of smoking was increased and of diabetes decreased in case versus control subjects. Overall, dipeptidyl peptidase IV activity (26.6±7.8 versus 29.6±7.3 nmol/mL per minute; P=0.026) and antigen (465.8±260.8 versus 563.1±208.6 ng/mL; P=0.017) were decreased in sera from individuals with Angiotensin-Converting Enzyme inhibitor-associated angioedema compared with Angiotensin-Converting Enzyme inhibitor-exposed control subjects without angioedema. Dipeptidyl peptidase IV activity (21.5±4.9 versus 29.8±6.7 nmol/mL per minute; P=0.001) and antigen (354.4±124.7 versus 559.8±163.2 ng/mL; P=0.003) were decreased in sera from cases collected during Angiotensin-Converting Enzyme inhibition but not in the absence of Angiotensin-Converting Enzyme inhibition. The degradation half-life of substance P correlated inversely with dipeptidyl peptidase IV antigen during Angiotensin-Converting Enzyme inhibition. Environmental or genetic factors that reduce dipeptidyl peptidase IV activity may predispose individuals to angioedema.

  • Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
    Hypertension, 2007
    Co-Authors: James Brian Byrd, Karine Touzin, Saba Sile, James V Gainer, Chang Yu, John H Nadeau, Albert Adam, Nancy J Brown

    Abstract:

    Angioedema is a potentially life-threatening adverse effect of Angiotensin-Converting Enzyme inhibitors. Bradykinin and substance P, substrates of Angiotensin-Converting Enzyme, increase vascular permeability and cause tissue edema in animals. Studies indicate that amino-terminal degradation of these peptides, by aminopeptidase P and dipeptidyl peptidase IV, may be impaired in individuals with Angiotensin-Converting Enzyme inhibitor–associated angioedema. This case-control study tested the hypothesis that dipeptidyl peptidase IV activity and antigen are decreased in sera of patients with a history of Angiotensin-Converting Enzyme inhibitor–associated angioedema. Fifty subjects with a history of Angiotensin-Converting Enzyme inhibitor–associated angioedema and 176 Angiotensin-Converting Enzyme inhibitor–exposed control subjects were ascertained. Sera were assayed for Angiotensin-Converting Enzyme activity, aminopeptidase P activity, aminopeptidase N activity, dipeptidyl peptidase IV activity, and antigen and the ex vivo degradation half-lives of bradykinin, des-Arg 9 -bradykinin, and substance P in a subset. The prevalence of smoking was increased and of diabetes decreased in case versus control subjects. Overall, dipeptidyl peptidase IV activity (26.6±7.8 versus 29.6±7.3 nmol/mL per minute; P =0.026) and antigen (465.8±260.8 versus 563.1±208.6 ng/mL; P =0.017) were decreased in sera from individuals with Angiotensin-Converting Enzyme inhibitor–associated angioedema compared with Angiotensin-Converting Enzyme inhibitor–exposed control subjects without angioedema. Dipeptidyl peptidase IV activity (21.5±4.9 versus 29.8±6.7 nmol/mL per minute; P =0.001) and antigen (354.4±124.7 versus 559.8±163.2 ng/mL; P =0.003) were decreased in sera from cases collected during Angiotensin-Converting Enzyme inhibition but not in the absence of Angiotensin-Converting Enzyme inhibition. The degradation half-life of substance P correlated inversely with dipeptidyl peptidase IV antigen during Angiotensin-Converting Enzyme inhibition. Environmental or genetic factors that reduce dipeptidyl peptidase IV activity may predispose individuals to angioedema.

James Brian Byrd – One of the best experts on this subject based on the ideXlab platform.

  • dipeptidyl peptidase iv in angiotensin converting Enzyme inhibitor associated angioedema
    Hypertension, 2008
    Co-Authors: James Brian Byrd, Karine Touzin, Saba Sile, James V Gainer, Chang Yu, John H Nadeau, Albert Adam, Nancy J Brown

    Abstract:

    Angioedema is a potentially life-threatening adverse effect of Angiotensin-Converting Enzyme inhibitors. Bradykinin and substance P, substrates of Angiotensin-Converting Enzyme, increase vascular permeability and cause tissue edema in animals. Studies indicate that amino-terminal degradation of these peptides, by aminopeptidase P and dipeptidyl peptidase IV, may be impaired in individuals with Angiotensin-Converting Enzyme inhibitor–associated angioedema. This case-control study tested the hypothesis that dipeptidyl peptidase IV activity and antigen are decreased in sera of patients with a history of Angiotensin-Converting Enzyme inhibitor–associated angioedema. Fifty subjects with a history of Angiotensin-Converting Enzyme inhibitor–associated angioedema and 176 Angiotensin-Converting Enzyme inhibitor–exposed control subjects were ascertained. Sera were assayed for Angiotensin-Converting Enzyme activity, aminopeptidase P activity, aminopeptidase N activity, dipeptidyl peptidase IV activity, and antigen and the ex vivo degradation half-lives of bradykinin, des-Arg 9 -bradykinin, and substance P in a subset. The prevalence of smoking was increased and of diabetes decreased in case versus control subjects. Overall, dipeptidyl peptidase IV activity (26.6±7.8 versus 29.6±7.3 nmol/mL per minute; P =0.026) and antigen (465.8±260.8 versus 563.1±208.6 ng/mL; P =0.017) were decreased in sera from individuals with Angiotensin-Converting Enzyme inhibitor–associated angioedema compared with Angiotensin-Converting Enzyme inhibitor–exposed control subjects without angioedema. Dipeptidyl peptidase IV activity (21.5±4.9 versus 29.8±6.7 nmol/mL per minute; P =0.001) and antigen (354.4±124.7 versus 559.8±163.2 ng/mL; P =0.003) were decreased in sera from cases collected during Angiotensin-Converting Enzyme inhibition but not in the absence of Angiotensin-Converting Enzyme inhibition. The degradation half-life of substance P correlated inversely with dipeptidyl peptidase IV antigen during Angiotensin-Converting Enzyme inhibition. Environmental or genetic factors that reduce dipeptidyl peptidase IV activity may predispose individuals to angioedema.

  • Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema. Commentary
    Hypertension, 2008
    Co-Authors: Eric Grouzmann, James Brian Byrd, Karine Touzin, Saba Sile, James V Gainer, John H Nadeau, Albert Adam, Thierry Buclin, Nancy J Brown

    Abstract:

    Angioedema is a potentially life-threatening adverse effect of Angiotensin-Converting Enzyme inhibitors. Bradykinin and substance P, substrates of Angiotensin-Converting Enzyme, increase vascular permeability and cause tissue edema in animals. Studies indicate that amino-terminal degradation of these peptides, by aminopeptidase P and dipeptidyl peptidase IV, may be impaired in individuals with Angiotensin-Converting Enzyme inhibitor-associated angioedema. This case-control study tested the hypothesis that dipeptidyl peptidase IV activity and antigen are decreased in sera of patients with a history of Angiotensin-Converting Enzyme inhibitor-associated angioedema. Fifty subjects with a history of Angiotensin-Converting Enzyme inhibitor-associated angioedema and 176 Angiotensin-Converting Enzyme inhibitor-exposed control subjects were ascertained. Sera were assayed for Angiotensin-Converting Enzyme activity, aminopeptidase P activity, aminopeptidase N activity, dipeptidyl peptidase IV activity, and antigen and the ex vivo degradation half-lives of bradykinin, des-Arg 9 -bradykinin, and substance P in a subset. The prevalence of smoking was increased and of diabetes decreased in case versus control subjects. Overall, dipeptidyl peptidase IV activity (26.6±7.8 versus 29.6±7.3 nmol/mL per minute; P=0.026) and antigen (465.8±260.8 versus 563.1±208.6 ng/mL; P=0.017) were decreased in sera from individuals with Angiotensin-Converting Enzyme inhibitor-associated angioedema compared with Angiotensin-Converting Enzyme inhibitor-exposed control subjects without angioedema. Dipeptidyl peptidase IV activity (21.5±4.9 versus 29.8±6.7 nmol/mL per minute; P=0.001) and antigen (354.4±124.7 versus 559.8±163.2 ng/mL; P=0.003) were decreased in sera from cases collected during Angiotensin-Converting Enzyme inhibition but not in the absence of Angiotensin-Converting Enzyme inhibition. The degradation half-life of substance P correlated inversely with dipeptidyl peptidase IV antigen during Angiotensin-Converting Enzyme inhibition. Environmental or genetic factors that reduce dipeptidyl peptidase IV activity may predispose individuals to angioedema.

  • Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
    Hypertension, 2007
    Co-Authors: James Brian Byrd, Karine Touzin, Saba Sile, James V Gainer, Chang Yu, John H Nadeau, Albert Adam, Nancy J Brown

    Abstract:

    Angioedema is a potentially life-threatening adverse effect of Angiotensin-Converting Enzyme inhibitors. Bradykinin and substance P, substrates of Angiotensin-Converting Enzyme, increase vascular permeability and cause tissue edema in animals. Studies indicate that amino-terminal degradation of these peptides, by aminopeptidase P and dipeptidyl peptidase IV, may be impaired in individuals with Angiotensin-Converting Enzyme inhibitor–associated angioedema. This case-control study tested the hypothesis that dipeptidyl peptidase IV activity and antigen are decreased in sera of patients with a history of Angiotensin-Converting Enzyme inhibitor–associated angioedema. Fifty subjects with a history of Angiotensin-Converting Enzyme inhibitor–associated angioedema and 176 Angiotensin-Converting Enzyme inhibitor–exposed control subjects were ascertained. Sera were assayed for Angiotensin-Converting Enzyme activity, aminopeptidase P activity, aminopeptidase N activity, dipeptidyl peptidase IV activity, and antigen and the ex vivo degradation half-lives of bradykinin, des-Arg 9 -bradykinin, and substance P in a subset. The prevalence of smoking was increased and of diabetes decreased in case versus control subjects. Overall, dipeptidyl peptidase IV activity (26.6±7.8 versus 29.6±7.3 nmol/mL per minute; P =0.026) and antigen (465.8±260.8 versus 563.1±208.6 ng/mL; P =0.017) were decreased in sera from individuals with Angiotensin-Converting Enzyme inhibitor–associated angioedema compared with Angiotensin-Converting Enzyme inhibitor–exposed control subjects without angioedema. Dipeptidyl peptidase IV activity (21.5±4.9 versus 29.8±6.7 nmol/mL per minute; P =0.001) and antigen (354.4±124.7 versus 559.8±163.2 ng/mL; P =0.003) were decreased in sera from cases collected during Angiotensin-Converting Enzyme inhibition but not in the absence of Angiotensin-Converting Enzyme inhibition. The degradation half-life of substance P correlated inversely with dipeptidyl peptidase IV antigen during Angiotensin-Converting Enzyme inhibition. Environmental or genetic factors that reduce dipeptidyl peptidase IV activity may predispose individuals to angioedema.

James V Gainer – One of the best experts on this subject based on the ideXlab platform.

  • dipeptidyl peptidase iv in angiotensin converting Enzyme inhibitor associated angioedema
    Hypertension, 2008
    Co-Authors: James Brian Byrd, Karine Touzin, Saba Sile, James V Gainer, Chang Yu, John H Nadeau, Albert Adam, Nancy J Brown

    Abstract:

    Angioedema is a potentially life-threatening adverse effect of Angiotensin-Converting Enzyme inhibitors. Bradykinin and substance P, substrates of Angiotensin-Converting Enzyme, increase vascular permeability and cause tissue edema in animals. Studies indicate that amino-terminal degradation of these peptides, by aminopeptidase P and dipeptidyl peptidase IV, may be impaired in individuals with Angiotensin-Converting Enzyme inhibitor–associated angioedema. This case-control study tested the hypothesis that dipeptidyl peptidase IV activity and antigen are decreased in sera of patients with a history of Angiotensin-Converting Enzyme inhibitor–associated angioedema. Fifty subjects with a history of Angiotensin-Converting Enzyme inhibitor–associated angioedema and 176 Angiotensin-Converting Enzyme inhibitor–exposed control subjects were ascertained. Sera were assayed for Angiotensin-Converting Enzyme activity, aminopeptidase P activity, aminopeptidase N activity, dipeptidyl peptidase IV activity, and antigen and the ex vivo degradation half-lives of bradykinin, des-Arg 9 -bradykinin, and substance P in a subset. The prevalence of smoking was increased and of diabetes decreased in case versus control subjects. Overall, dipeptidyl peptidase IV activity (26.6±7.8 versus 29.6±7.3 nmol/mL per minute; P =0.026) and antigen (465.8±260.8 versus 563.1±208.6 ng/mL; P =0.017) were decreased in sera from individuals with Angiotensin-Converting Enzyme inhibitor–associated angioedema compared with Angiotensin-Converting Enzyme inhibitor–exposed control subjects without angioedema. Dipeptidyl peptidase IV activity (21.5±4.9 versus 29.8±6.7 nmol/mL per minute; P =0.001) and antigen (354.4±124.7 versus 559.8±163.2 ng/mL; P =0.003) were decreased in sera from cases collected during Angiotensin-Converting Enzyme inhibition but not in the absence of Angiotensin-Converting Enzyme inhibition. The degradation half-life of substance P correlated inversely with dipeptidyl peptidase IV antigen during Angiotensin-Converting Enzyme inhibition. Environmental or genetic factors that reduce dipeptidyl peptidase IV activity may predispose individuals to angioedema.

  • Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema. Commentary
    Hypertension, 2008
    Co-Authors: Eric Grouzmann, James Brian Byrd, Karine Touzin, Saba Sile, James V Gainer, John H Nadeau, Albert Adam, Thierry Buclin, Nancy J Brown

    Abstract:

    Angioedema is a potentially life-threatening adverse effect of Angiotensin-Converting Enzyme inhibitors. Bradykinin and substance P, substrates of Angiotensin-Converting Enzyme, increase vascular permeability and cause tissue edema in animals. Studies indicate that amino-terminal degradation of these peptides, by aminopeptidase P and dipeptidyl peptidase IV, may be impaired in individuals with Angiotensin-Converting Enzyme inhibitor-associated angioedema. This case-control study tested the hypothesis that dipeptidyl peptidase IV activity and antigen are decreased in sera of patients with a history of Angiotensin-Converting Enzyme inhibitor-associated angioedema. Fifty subjects with a history of Angiotensin-Converting Enzyme inhibitor-associated angioedema and 176 Angiotensin-Converting Enzyme inhibitor-exposed control subjects were ascertained. Sera were assayed for Angiotensin-Converting Enzyme activity, aminopeptidase P activity, aminopeptidase N activity, dipeptidyl peptidase IV activity, and antigen and the ex vivo degradation half-lives of bradykinin, des-Arg 9 -bradykinin, and substance P in a subset. The prevalence of smoking was increased and of diabetes decreased in case versus control subjects. Overall, dipeptidyl peptidase IV activity (26.6±7.8 versus 29.6±7.3 nmol/mL per minute; P=0.026) and antigen (465.8±260.8 versus 563.1±208.6 ng/mL; P=0.017) were decreased in sera from individuals with Angiotensin-Converting Enzyme inhibitor-associated angioedema compared with Angiotensin-Converting Enzyme inhibitor-exposed control subjects without angioedema. Dipeptidyl peptidase IV activity (21.5±4.9 versus 29.8±6.7 nmol/mL per minute; P=0.001) and antigen (354.4±124.7 versus 559.8±163.2 ng/mL; P=0.003) were decreased in sera from cases collected during Angiotensin-Converting Enzyme inhibition but not in the absence of Angiotensin-Converting Enzyme inhibition. The degradation half-life of substance P correlated inversely with dipeptidyl peptidase IV antigen during Angiotensin-Converting Enzyme inhibition. Environmental or genetic factors that reduce dipeptidyl peptidase IV activity may predispose individuals to angioedema.

  • Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
    Hypertension, 2007
    Co-Authors: James Brian Byrd, Karine Touzin, Saba Sile, James V Gainer, Chang Yu, John H Nadeau, Albert Adam, Nancy J Brown

    Abstract:

    Angioedema is a potentially life-threatening adverse effect of Angiotensin-Converting Enzyme inhibitors. Bradykinin and substance P, substrates of Angiotensin-Converting Enzyme, increase vascular permeability and cause tissue edema in animals. Studies indicate that amino-terminal degradation of these peptides, by aminopeptidase P and dipeptidyl peptidase IV, may be impaired in individuals with Angiotensin-Converting Enzyme inhibitor–associated angioedema. This case-control study tested the hypothesis that dipeptidyl peptidase IV activity and antigen are decreased in sera of patients with a history of Angiotensin-Converting Enzyme inhibitor–associated angioedema. Fifty subjects with a history of Angiotensin-Converting Enzyme inhibitor–associated angioedema and 176 Angiotensin-Converting Enzyme inhibitor–exposed control subjects were ascertained. Sera were assayed for Angiotensin-Converting Enzyme activity, aminopeptidase P activity, aminopeptidase N activity, dipeptidyl peptidase IV activity, and antigen and the ex vivo degradation half-lives of bradykinin, des-Arg 9 -bradykinin, and substance P in a subset. The prevalence of smoking was increased and of diabetes decreased in case versus control subjects. Overall, dipeptidyl peptidase IV activity (26.6±7.8 versus 29.6±7.3 nmol/mL per minute; P =0.026) and antigen (465.8±260.8 versus 563.1±208.6 ng/mL; P =0.017) were decreased in sera from individuals with Angiotensin-Converting Enzyme inhibitor–associated angioedema compared with Angiotensin-Converting Enzyme inhibitor–exposed control subjects without angioedema. Dipeptidyl peptidase IV activity (21.5±4.9 versus 29.8±6.7 nmol/mL per minute; P =0.001) and antigen (354.4±124.7 versus 559.8±163.2 ng/mL; P =0.003) were decreased in sera from cases collected during Angiotensin-Converting Enzyme inhibition but not in the absence of Angiotensin-Converting Enzyme inhibition. The degradation half-life of substance P correlated inversely with dipeptidyl peptidase IV antigen during Angiotensin-Converting Enzyme inhibition. Environmental or genetic factors that reduce dipeptidyl peptidase IV activity may predispose individuals to angioedema.